Nuclera, the Cambridge-based biotechnology company focused on accelerating protein expression and optimisation, has appointed William J. Kullback to its Board of Directors. The appointment comes as the company implements its global commercial strategy following a successful $75 million series C funding round.
Glox Therapeutics has announced strategic appointments to accelerate the development of its novel bacteriocin-based antibiotic platform, with Dr Michael Murray joining as Chair and Dr Nel Moore strengthening the Scientific Advisory Board. The Glasgow-based biotechnology company is pioneering a distinctive approach to combating antimicrobial resistance (AMR) through engineered protein bacteriocins that selectively target drug-resistant pathogens.
Eleva, the Freiburg-based biopharmaceutical company specialising in difficult-to-produce biologics via its proprietary moss-based expression system, has announced a significant addition to its leadership team as it prepares to enter a crucial clinical development phase.
by Dr Aleksandra Havelka Assays for NT-proBNP form a key part of diagnosing/ruling out, predicting and managing heart failure. CLI chatted to Dr Aleksandra Havelka (Gentian Diagnostics) to find out more about the challenges and limitations of measuring NT-proBNP concentrations, particularly the effects of glycosylation, and what developments are on the horizon to overcome these […]
by Dr Osaretin Emmanuel Asowata The detection of Pneumocystis jirovecii in immunocompromised patients is crucial for the treatment of Pneumocystis jirovecii pneumonia (PCP) and to prevent invasive infection. However, PCP can be challenging to diagnose clinically, as symptoms are non-specific. There are several laboratory methods that can be used to diagnose PCP and their advantages […]
University of Bern makes landmark move to AWS-powered HALO AP platform for diagnostic tissue analysis
Laboratories are among the most resource-intensive environments in scientific research, consuming vast quantities of energy, water, and disposable materials. However, a growing movement towards sustainable laboratory practices is gaining momentum within the bioanalytical sector, as evidenced by Synexa Life Sciences’ recent achievement.
Cambridge-based JuliaHub is strengthening its position in the pharmaceutical sector with significant investment in its CFR Part 11-compliant platform, offering integrated solutions for pharmacometrics, modelling and regulatory compliance.
The biotechnology sector marks a significant advancement in genetic medicine with EG 427’s achievement in treating neurogenic bladder using a novel herpes-based vector approach.
In a significant development for radiopharmaceutical advancement, isotope technology provider Eckert & Ziegler has established a comprehensive partnership with Bicycle Therapeutics to supply radioisotopes and manufacture novel bicyclic peptide-based radiopharmaceuticals for upcoming clinical trials.
March 2026
Prins Hendrikstraat 1
5611HH Eindhoven
The Netherlands
info@clinlabint.com
PanGlobal Media is not responsible for any error or omission that might occur in the electronic display of product or company data.